Nov 2018

WORLD-FIRST MEDICINAL CANNABIS TRIAL TO TREAT BRAIN CANCER

A new world-first trial will examine whether oral medicinal cannabis can affect tumour growth in patients with glioma, a common type of brain cancer. As well as supporting the standard treatment for a brain tumour, researchers also hope that medicinal cannabis will have a positive impact on patient’s quality of life. Read the article here.

One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.

READ MORE >

In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.

READ MORE >

What’s most important in business – purpose or profit? At ANTG we get to achieve both.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >